You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Zolmitriptan - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for zolmitriptan and what is the scope of patent protection?

Zolmitriptan is the generic ingredient in three branded drugs marketed by Padagis Israel, Amneal, Alembic, Apotex Inc, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Rising, Zydus Pharms Usa Inc, Astrazeneca, Ajanta Pharma Ltd, Ani Pharms, Appco, Aurobindo Pharma, Invagen Pharms, Natco Pharma Usa, Orbion Pharms, Pld Acquisitions Llc, Sun Pharma Global, Zydus Pharms, and IPR, and is included in twenty-six NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for zolmitriptan. Twenty-one suppliers are listed for this compound.

Drug Prices for zolmitriptan

See drug prices for zolmitriptan

Recent Clinical Trials for zolmitriptan

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Parc de Salut MarPhase 1
Food and Drug Administration (FDA)Phase 1
William StoopsEarly Phase 1

See all zolmitriptan clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for zolmitriptan
Paragraph IV (Patent) Challenges for ZOLMITRIPTAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZOMIG Nasal Spray zolmitriptan 2.5 mg/spray 021450 1 2016-06-09
ZOMIG Nasal Spray zolmitriptan 5 mg/spray 021450 1 2013-11-14

US Patents and Regulatory Information for zolmitriptan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Macleods Pharms Ltd ZOLMITRIPTAN zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 204336-002 Oct 22, 2015 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising ZOLMITRIPTAN zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 202855-002 Sep 20, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glenmark Pharms Ltd ZOLMITRIPTAN zolmitriptan TABLET;ORAL 201779-001 May 14, 2013 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Jubilant Generics ZOLMITRIPTAN zolmitriptan TABLET;ORAL 202279-001 Nov 20, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for zolmitriptan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amneal ZOMIG zolmitriptan SPRAY;NASAL 021450-004 Sep 30, 2003 ⤷  Sign Up ⤷  Sign Up
Amneal ZOMIG zolmitriptan SPRAY;NASAL 021450-003 Sep 16, 2013 ⤷  Sign Up ⤷  Sign Up
Ipr ZOMIG zolmitriptan TABLET;ORAL 020768-002 Nov 25, 1997 ⤷  Sign Up ⤷  Sign Up
Ipr ZOMIG zolmitriptan TABLET;ORAL 020768-001 Nov 25, 1997 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.